{
    "clinical_study": {
        "@rank": "43549", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1 healthy subjects and subjects with mild hepatic impairment Day 1 = Each subject will receive a single dose of 100 mg IDX719, as 2 x 50 mg tablets"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 2 healthy subjects and subjects with moderate hepatic impairment Day 1 = Each subject will receive a single dose of 100 mg IDX719, as 2 x 50 mg tablets."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 3 healthy subjects and subjects with severe hepatic impairment Day 1 = Each subject will receive a single dose of 100 mg IDX719, as 2 x 50 mg tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and\n      tolerability of single-dose administration of IDX719 in subjects with normal hepatic\n      function and subjects with varying degrees of hepatic impairment."
        }, 
        "brief_title": "To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read and sign the written informed consent form (ICF) after the nature of the study\n             has been fully explained.\n\n          -  All subjects of childbearing potential must have agreed to use a double method of\n             birth control (one of which must be a barrier) from Screening through at least 90\n             days after the last dose of the study drug.\n\n          -  Male subjects have agreed not to donate sperm from Day -1 through 90 days after the\n             last dose of study drug.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding.\n\n          -  Other clinically significant medical conditions or laboratory abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919125", 
            "org_study_id": "IDX-06A-008"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3"
            ], 
            "description": "IDX719 will be supplied as a 50 mg tablet", 
            "intervention_name": "IDX719", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic hepatitis C", 
            "Hepatitis C virus", 
            "HCV"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami, Division of Clinical Pharmacology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PK measures of plasma drug exposure and elimination (AUC0-inf, Cmax, t1/2) of IDX719", 
            "measure": "PK Evaluation of IDX719", 
            "safety_issue": "No", 
            "time_frame": "6 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportions of subjects experiencing adverse events.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "6 days"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}